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TREATMENT OF SEVERE MULTIPLE SCLEROSIS WITH MELPHALAN
AND TOTAL LYMPHOID IRRADIATION FOLLOWED BY AUTOLOGOUS
STEM CELL TRANSPLANTATION
Ferreira, A.1; Miller, W.E.1; Andrey, J.W.1; McMillan, R.2; Tripura-
neni, P.1; Romine, J.S.1; Sipe, J.C.1; Burian, C.1; Mason, J.R.1
1. Scripps Clinic, La Jolla, CA; 2. The Scripps Research Institute, La
Jolla, CA
Objective: To evaluate the safety and therapeutic efficacy of
melphalan and TLI followed by autologous CD34+ selected stem
cells for patients with primary or secondary progressive multiple
sclerosis. Methods: Peripheral blood stem cells were mobilized
with cyclophosphamide at 1.5 g/m2 and G-CSF 10 µg/kg/day
beginning 24 hours after cyclophosphamide until completion of
stem cell harvesting. Products were CD34 selected using Isolex
300i. Transplant preparative regimen consisted of high dose mel-
phalan at 140 mg/m2 IV over 30 minutes on day -4 and TLI 300
cGy bid on days -2 and -1 with stem cell infusion on day 0. G-
CSF (5 µg/kg sc) was administered from day 0 until ANC >
1500/µl for 3 consecutive days. Results: Eight patients with severe
multiple sclerosis and a median age of 45 (range 32 to 56) have
been enrolled in the study. Neutrophil (ANC > 500) and platelet
(> 100,000) recovery occurred by day 9 (range 8 to 10) and day 17
(range 15 to 20), respectively. A median of 2 red cell transfusions
(range 0 to 2) and a median of 2 (range 1 to 2) single donor units
of platelets were required. The median number of CD34 positive
cells x 106/kg collected and infused was 10.9 (range 4.5 to 25.9)
and 8.2 (range 4.5 to 12.9). The median number of T cells (CD3)
x 104/kg infused was 9.9 (range 1.4 to 52.6). No grade 3-4 non-
hematologic toxicity was observed. Transient neutropenic fever
occurred in 2 patients, one patient developed microscopic hema-
turia and had a positive urine culture for BK virus. Day 100 sur-
vival was 100%. Conclusion: Overall, the toxicities from high dose
melphalan and TLI have been minimal conﬁrming that this regi-
men is a feasible and safe treatment in patients with severe multi-




HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE
MYELOID LEUKEMIA IN REMISSION
Ball, E.D.; Davis, B.N.; Holman, P.; Bashey, A.; Carrier, E.; Chen, J.;
Kormanik, P.; Corringham, S. UCSD Medical Center, San Diego, CA
Peripheral blood stem cell transplantation (PBSCT) is increas-
ingly employed as consolidation therapy for patients with standard
to high-risk acute myeloid leukemia (AML) in ﬁrst remission. We
report on 9 AML patients who underwent an autologous PBSCT
between May, 2000 - June, 2001, using a modiﬁcation of the regi-
men reported by Linker (Biol. of Blood and Marrow Trans. 6:50-
57, 2000) to lower toxicity for the relatively mature patients seen
at our center. After achieving remission with cytosine-arabi-
noside-based induction, 8/9 patients underwent consolidation
with cytarabine (2 g/m2 every 12 hours) and etoposide (10
mg/kg/day) for 3 days (reduced from 4 days). One patient received
the 4 day regimen. All patients received the preparative regimen
of intravenous busulfan (12.8 mg/kg) over 4 days and cytoxan (120
mg/kg, IV) over 2 days. Four patients were diagnosed with FAB
subtype M2, 3 with M5, 1 with M4, and 1 with M6. At diagnosis,
cytogenetics were normal for 6 patients and abnormal for 3
patients [46XX, der (19) t(11;9) (q13,q13); 46X, t(9;22)
(q34;q11.2); 45X, -Y(3)/ 46XY,(cp16)]. The median WBC count
at diagnosis was 59.7 (x109 /L). All patients were in complete
remission (CR) (CR1: 7; CR2: 2) at the time of transplant. The
median age of all patients was 61 years (range 22-70). The median
CD34+ cell dose infused was 5.46 (x106 /kg). There were no treat-
ment-related deaths nor cases of hepatic veno-occlusive disease.
Four patients relapsed at a median of 4.1 months post-PBSCT (1
in CR2, 3 in CR1). Five patients remain in CR at a median of 9.6
months post-PBSCT. This retrospective study in relatively
mature AML patients, many with high-risk features, demonstrates
the safety of the modified regimen (reduced dose of ara-C and
etoposide, intravenous Bu) and provides an alternative to non-
stem cell supported repetitive consolidation regimens for this pop-
ulation of patients.
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ONCE DAILY INTRAVENOUS BUSULFAN (BUSULFEX) AND
CYCLOPHOSPHAMIDE FOLLOWED BY STEM CELL TRANSPLANT FOR
HEMATOLOGIC MALIGNANCIES: DOSING MODIFICATION PROTOCOL
Day, S.D.1; McGuirk, J.P.1; Picken, S.1; Reed, M.2; Copelan, E.A.3;
Leather, H.L.4; Wingard, J.R.4; Geller, R.B.5; Abhyankar, S.1;
Lennon, S.6 1. Oncology and Hematology Associates of Kansas City, Kansas
City, MO; 2. Case Western University, Cleveland, OH; 3. Ohio State Uni-
versity, Cleveland, OH; 4. University of Florida, Gainesville, FL; 5. Uni-
versity of Arizona, Phoenix, AZ; 6. Orphan Medical, Minnetonka, MN
In a ﬁve cohort escalation protocol, we sought to determine the
safety, efﬁcacy, and PK proﬁle of once daily IV busulfan (IVBu) com-
bined with cyclophosphamide (CY), and thus, the feasibility of outpa-
tient administration of this regimen. Twelve hospitalized pts
(NHL=6, AML=2, CML=1, MDS=1, HD=1, MM=1; autoPB-
SCT=8, alloPBSCT=4) received IVBu for 4 days followed by CY
60mg/kg/d IV for 2 days. In cohort 1, 4 pts received IVBu 1.6mg/kg
over 4h q12hx2, then 0.8mg/kg over 2h q6hx12. In cohort 2, 4 pts
received IVBu 1.6mg/kg over 2h q12hx2, then 1.6mg/kg over 4h
q12hx2, then 0.8mg/kg over 2h q6hx8. In cohort 3, 4 pts received
IVBu 3.2mg/kg over 4h q24hx1, then 1.6mg/kg over 2h q12hx2, then
0.8mg/kg over 2h q6hx8. Multiple timed blood samples from ﬁrst
and last days of IVBu were analyzed centrally for busulfan concentra-
tion by gas chromatography. Pts achieved an ANC>500 and plt>20K
by median day 13.5 (10-19) and day 16.5 (13-50), respectively. No pt
experienced toxicities limiting cohort escalation. One pt in cohort 2
developed moderate VOD on day 18 that resolved by day 53. Toxici-
ties were mild to moderate and included nausea, vomiting, diarrhea,
mucositis, and increased LFTs. With median follow-up of 193d (61-
370d), 2 pts have expired (relapse on d203 and GVHD on d207). PK
data (expressed as mean ± std. dev. below) are linear, demonstrate
proportional increases in AUC, and are associated with limited vari-
ability. We continue to enroll pts with the last cohort scheduled to
receive IVBu 3.2mg/kg/d IV q24hx4. Dose modiﬁcation of IVBu
appears safe, effective, and feasible for outpatient administration.
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PREDICTING SUCCESSFUL PERIPHERAL BLOOD STEM CELL (PBSC)
COLLECTION USING PERIPHERAL WBC AND CD34+ CELL COUNTS: A
COST ANALYSIS
Heller, B.J.; Ornstein, D.L.; Hensley, R.; Ririe, D.W.; Shaughnessy, P.J.;
Bee, C.; Reilly, P.A. Wilford Hall Medical Center, Lackland AFB, TX
Background: Collection of sufficient PBSC for engraftment
using the fewest leukapheresis sessions possible serves to minimize
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patient risk and overall expenditure. Peripheral blood (PB) WBC
count has been shown to be a poor indicator for successful PBSC
collection, whereas PB CD34+ cell count may be a more reliable
predictor. We undertook this study to determine the use of PB
CD34+ cell counts to optimize the timing of PBSC collection.
Methods: Consecutive PBSC donors (n = 163) were mobilized
using growth factors and chemotherapy. PB WBC and PB CD34+
cell counts were determined with each leukapheresis session and
the total CD34+ cell count was determined for the leukapheresis
product (LP) from each session. The following correlations were
then obtained: PB WBC and PB CD34+ cell counts, PB WBC
and LP CD34+ cell counts, and PB CD34+ and LP CD34+ cell
counts. Results: There was a poor correlation between PB WBC
and LP CD34+ cell counts (r = 0.21). There was a signiﬁcant cor-
relation, however, between PB CD34+ and LP CD34+ cell counts
(r = 0.70). When successful leukapheresis was deﬁned as a collec-
tion of a LP containing 2.0 x 106 CD34+ cells/kg recipient body
weight, the PB CD34+ but not the WBC count predicted success-
ful collection. The table gives percentage of successful collections
in one session. Additionally, the use of peripheral CD 34+ count
to predict successful collection would provide a cost savings of
approximately $45,000 per 100 patients.
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SUPPORTIVE CARE REQUIREMENTS OF AUTO & MATCHED SIB-
LING TRANSPLANT RECIPIENTS IN THE FIRST 30 DAYS POST
TRANSPLANT
Sangam, S.; Dorr, S.; Garner, P.; Akhtar, A.; Momin, F. Oakwood
Hospital, Dearborn, MI
Purpose: To quantify transfusion, nutritional support, antibi-
otic and cytokine requirements of stem cell transplant (SCT)
recipients in the first 30 days post SCT. Methods: 54 autografts
and 20 allografts were studied from day of admission to day +30
post SCT. The following were the criteria for supportive care:
Unless the patient was bleeding or unstable the following
guidelines were followed. 1. Two units PRBC transfused for
hemoglobin of 8 gms/dl or less. 2. Six units of random donor
platelets transfused for a platelet count of 15,000 or lower.
3.Empiric antibiotics included Ceftazidime for febrile neu-
tropenia. Vancomycin was added if warranted. 4. G-CSF was
given from day +1 until the ANC was > 500 for 3 consecutive
days. 5. TPN was initiated when PO intake was reduced and
continued until oral intake was reestablished. 6. Hospital stay.
Results: Of the 54 autografts 24 were done for Breast Cancer,
24 for hematological malignancies and 7 for testicular and
Ovarian Cancer. Median age was 50 yr. (21 - 72). Twenty were
males and 34 were female. There were 10 male and 10 female
allogeneic recipients with a median age of 53 yr. (24 to 69). All
allografts had myeloablative regimens. Conclusions: Uncompli-
cated autologous and allograft recipients treated on standard
protocols using myeloablative regimens have a predictable hos-
pital stay, requirement of transfusions, nutrition support,
cytokine and antibiotics. Besides providing quality control and
consistency, this data in combination with the cost of other
drugs and laboratory tests could also aid in computing the ini-
tial cost of uncomplicated autologous and allogeneic stem cell
transplantation.
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A PHASE II TRIAL OF HIGH DOSE CHEMOTHERAPY AND CONCUR-
RENT RITUXIMAB FOLLOWED BY AUTOLOGOUS PERIPHERAL STEM
CELL TRANSPLANTATION FOR TREATMENT OF RELAPSED CD20 POS-
ITIVE B-CELL NON-HODGKIN’S LYMPHOMA
Vusirikala, M.; Stein, R.S.; Brandt, S.; Morgan, D.; Greer, J.; Jaga-
sia, M.; Kassim, A.; Schuening, F.; Goodman, S. Vanderbilt University
Medical Center, Nashville, TN
Introduction: High dose therapy (HDT) with autologous stem
cell transplantation (ASCT) improves event-free survival in
patients with relapsed NHL. However, 40-60% of patients subse-
quently relapse. An attempt to improve outcome after ASCT has
been made by addition of Rituximab as adjuvant therapy. To date,
several investigators have reported safe and effective use of Ritux-
imab prior to stem cell collection (in-vivo purging) and/or at time
of hematopoietic recovery following ASCT. Several studies have
also observed cytoreductive synergism when Rituximab is admin-
istered concurrently with chemotherapy. The purpose of our
phase II trial was to extend these observations of synergism to the
HDC/ASCT situation. Methods: We treated 7 patients (M:F=3:4;
median age at transplant=62 yrs) with NHL (diffuse large cell 3,
transformed large cell 2, mantle cell 1 and follicular center cell
grade-II 1) with ASCT. All patients received cyclophosphamide
7200mg/m2, BCNU 400mg/m2 and etoposide 2400mg/m2
(CBV) for conditioning and unpurged stem cells. Rituximab at
125mg/m2 was administered on days –6, -5, -4 and at 375mg/m2
on days +1, +8 and +15. Toxicity, survival and relapse were meas-
ured. Results: All 7 patients completed planned therapy. Median
duration of follow up was 174 days (122-370). Engraftment was
achieved in all patients with median day to ANC>500/µL of 13
days (10-18) and platelets>20,000/µL of 13 days (8-41). No
patients developed grade III or greater non-hematologic toxicity.
2/7 patients developed persistent neutropenia (grade II-III) post-
engraftment requiring G-CSF, 3/7 patients had delayed thrombo-
cytopenia (grade II-III) and one patient had candida esophagitis
after engraftment. All patients survived past 100 days post-trans-
plant. 1/7 pts has relapsed and no deaths have occurred to date.
Conclusion: Although the number of patients is small, our results
demonstrate the safety of concurrent use of Rituximab with HDC.
Longer follow up and larger randomized studies are required to
prove efﬁcacy of this treatment approach.
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A CD34 PREDICTION MODEL
Bakkestad-Legare, P.1,2; Tulloch, M.1,2; Giftakis, A.1,2; Hacking, K.1,2;
Rubinger, M.1,2 1. Cancercare Manitoba, Winnipeg, MB, Canada;
2. Hematopoietic Stem Cell Lab, Winnipeg, MB, Canada
Blood CD34 has been performed in our centre since 1998 to
determine the optimal apheresis timing of Peripheral Blood Prog-
enitor Cells (PBPC) from autologous Blood and Marrow trans-
plants (BMT) patients. Some centres sample the product for
CD34+cells during apheresis in order to determine whether the
PBPC product is sufﬁcient. This practice may result in possible
product contamination and increase resource time. Cell-kinetic
models of predictive algorithm for Blood CD34 have been used to
determine the CD34+/kg in the apheresis collection. Our centre
retrospectively evaluated 38 patients who underwent 53 consecu-
tive PBPC collections. Their diagnoses were Non-Hodgkin’s lym-
phoma (N=14), Hodgkin’s (N=9) and Multiple Myeloma (N=15).
Blood CD34 and the CD34+/kg in the corresponding PBPC were
analyzed using a CD34 prediction model (previously reported at
ISHAGE June, 2001). The correlation was significant with a r2
value = 0.9890 and a p value = < 0.0001. A prospective study is
underway using the CD34 prediction model to determine the vol-
ume of apheresis required to reach the desired CD34+/kg. To
date, 14 patients have undergone 21 PBPC collections. Their
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diagnoses were Non-Hodgkin’s lymphoma (N=5), Hodgkin’s dis-
ease (N=1) and Multiple Myeloma (N=8). All patients received
chemo-mobilization and granulocyte colony stimulating factor
(G-CSF), with the addition of stem cell factor for two patients.
Blood CD34 is tested once the patient’s counts white blood count
is beginning to rise after nadir. Differences were noted between
disease states and corresponding mobilizing chemotherapy. Col-
lection efﬁciencies for the COBE Spectra, the apheresis machine
used for PBPC collections are examined for each patient. Only 3
of 21 Apheresis products had a lower CD34+/kg than what was
predicted. Using the CD34 prediction model, the required vol-
ume for apheresis to achieve the desired CD34+/kg cell dose can
be speciﬁcally designed for each patient, thus allowing for an opti-
mized collection.
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DOES ABO AND RH INCOMPATIBILITY BETWEEN DONOR AND
RECIPIENT INFLUENCE GVHD INCIDENCE?
Barone, B.; Paiva, T.C.; Bouzas, L.S.; Barbosa, M.L.; Maciel, C.M.;
Paraguassu-Braga, F.H.; Lerner, D.; da Matta, J.; Tavares, R.C.;
Tabak, D.G. INCA, Rio de Janeiro, Brazil
The incompatibilities of the ABO blood system and the Rh
imunophenotyping between donor and patient do not represent
an obstacle condition to bone marrow transplantation (BMT), but
the quality of patient’s life can be greatly inﬂuenced by the severi-
ty of Graft-versus-host disease (GVHD), the most important
BMT complication. This retrospective study was carried out with
65 transplanted patients from 1996 to 2000 that had any ABO
blood (major or minor) and Rh incompatibility. Comparing the
results to a group control with the same number of transplanted
patients, whose donors were completely ABO and Rh compatible,
we analyzed if this type of incompatibility was able to increase the
GVHD frequency. The marrow products were processed with
standardized methods and the imunohematologic typing was car-
ried out using assay tubes with standard reagents. Nevertheless,
GVHD frequency was increased in the group with ABO blood
system incompatibility, considering the group control, this differ-
ence wasn’t statistically signiﬁcant: chronic GVHD was present in
32 patients (49,2%) with similar ABO system and in 39 individuals
(60,0%) with any blood incompatibility (p = 0.2905); acute
GVHD was found in 17 patients (26.2%) in the group control,
against 24 patients (36.9%) with ABO blood system incompatibili-
ties (p = 0.2574). Although complementary data, in a large number
of individuals, would be necessary to confirm this findings, and
knowing that other factors can directly increase the incidence of
GVHD, the ABO system would be an auxiliary tool in the BMT
donor selection process.
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CD34+ SELECTION OF PBSC AND BM BY IMMUNOMAGNETIC
METHOD (ISOLEX 300I). EVALUATION OF THE SYSTEM, THE QUALI-
TY OF PRODUCTS AND TUMOR DEPLETION
Desbois, I.1; Colombat, P.2; Roingeard, P.3; Degenne, M.4; Ducrot, T.5;
Domenech, J.4; Georget, M.4; Lefevre, M.1; Binet, C.4; Delain, M.2
1. Cellular Therapy Lab - Centre Atlantique Blood Bank, Tours, France;
2. Dpt of Oncology - Univ Hospital, Tours, France; 3. Dpt of Microscopy
- Univ Hospital, Tours, France; 4. Lab of Hematology - Univ Hospital,
Tours, France; 5. Nexell International, Wemmel, Belgium
The purpose of this study was to analyse the efficiency of the
automated system for CD34 selection in auto stem cells transplan-
tation (ASCT) for NHL or CLL. ASCT support for HDC
improves long term survival in those cases but the risk of reinfused
tumor cells to the patients could participated to the releapse.
CD34+ selection can improve the depletion in residual disease.
From 1997 to 2001, 36 patients with low grade NHL and stage B
or C CLL were transplanted with selected stem cells (Isolex 300i
with 3 versions v1.12;v2.0b1;V2.5) from PBSC (n=18) or BM
(n=18). The selection was done just after collection for PBSC and
on the ﬁcolled fraction for BM. After selection, the mean purity
was 98.8% for PBSC and 91.1% for BM. The overall yield
obtained was at 54.5% for PBSC and 44.2% for BM with a signiﬁ-
cant increase with the latest version (respectively 63.3% and
74.6%). In conclusion, the Isolex system can provide a very high
purity in CD34+ cells. The yield was better when PBSC were
selected in comparison with BM probably because of a higher cel-
lular homogeneity. We have also obtained better performances
with the version 2.5 of the Isolex. For each PBSC, we have
obtained a good quality of products in terms of CD34+/Kg and
CFU GM (results will be described). Regarding the tumoral
depletion, our results are really encouraging and more particularly
for CLL.
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HIGHER FREEZING CONCENTRATIONS AND ENGRAFTMENT
Dozier, M.M.; Dicke, K.A.; Gandy, J.; Patel, M. Arlington Cancer
Center, Arlington, TX
At Arlington Cancer Center, we analyzed reinfusions on 20
patients (14 breast cancer, 3 NHL, 1 Hodgkin’s lymphoma, 1 Mul-
tiple Myeloma and 1 AML) between 1999-2000 were analyzed for
final CD34 x 10*6 cells/kg, WBC concentration of the frozen
apheresis product and the effect WBC concentration had on days to
ANC recovery to 500 cells/mm3 and platelet recovery to
20,000/mm3. Reinfusions were usually administered over two con-
secutive days with standard of care antibiotic and antifungal sup-
port. The median WBC concentration x 10*6/ml was 510 (183-
890). There was no significant difference between days to ANC
recovery or platelet recovery between reinfusions of products frozen
at > 500 x10*6 WBC/ml(N=18 reinfusions) and products frozen at <
500 x10*6 WBC/ml(N=12 reinfusions), (14+4 days vs 13+3 days (p
value=0.14) for ANC recovery and 16+11 days vs 14+9 days(p
value=0.24) for platelet recovery respectively). The concentration of
CD34 cells/kg of body weight was higher in the patients receiving
apheresis products at concentrations less than 500 WBC/ml (5 x
10*6/kg vs 3.5 x 10*6 kg, p value = 0.028). For those patients who
mobilize at less than optimal CD34 percentage of apheresis prod-
uct, freezing at higher WBC concentrations allows for a reduction
in volume and therefore a reduction in DMSO usage, fewer bags
thus less freezer space used. Freezing at higher WBC concentra-
tions does not appear to have an effect on days to ANC recovery to
500 cells/mm3 or platelet recovery to 20,000/mm3.
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SUPPRESSION OF EPSTEIN BARR VIRUS (EBV) RELEASE FROM IRRA-
DIATED B LYMPHOBLASTOID CELL LINES (BLCL): SUPERIOR ACTIVI-
TY OF GANCICLOVIR COMPARED TO ACYCLOVIR
Keever-Taylor, C.A.; Behn, B.; Konings, S.; Orentas, R.J.; Davies, B.;
Margolius, D.A. Medical College of Wisconsin, Milwaukee, WI
BLCL generated by exposure of patient or donor B cells to a
laboratory strain of EBV are commonly utilized in the preparation
of T cell lines or clones used for post-transplant immunotherapy.
Up to 5% of cells within the BLCL may contain infectious virus
that could be released after stress such as that caused by irradia-
tion. To reduce this risk, laboratories have included acyclovir (an
inhibitor of DNA polymerase) at 100 mM in the BLCL cultures
for ≥14 days prior to use. Validation studies were performed to
determine the effectiveness of acyclovir in preventing EBV release
through use of co-culture assays with cord blood mononuclear
cells (CBMC) (ratio of 2:1 CBMC to BLCL). Both previously cry-
opreserved and freshly growing BLCL treated in the absence or
presence of acyclovir were tested. The results showed that the
irradiated BLCL (7,500 cGy) resulted in transformation of >85%
of the CBMC co-cultures (N=104) regardless of acyclovir-treat-
ment. Furthermore, doubling time of the BLCL was signiﬁcantly
reduced during acyclovir exposure. Additional CBMC co-culture
experiments were performed using BLCL maintained for 14 days
in ganciclovir at 0.5 and 1.0 µg/mL of culture. Here we found B
cell transformation in 3/6 (50%) of cultures at 0.5 µg/mL and 2/6
(33%) of cultures at 1.0 µg/mL. CBMC co-cultures using BLCL
grown in ganciclovir at 2.0 and 4.0 µg/mL have just been initiated.
BLCL grew normally during the two-week treatment period at all
doses of ganciclovir tested to date. While still preliminary, these
results indicate that ganciclovir is more effective at preventing
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release of infectious EBV from irradiated BLCL than acyclovir
and is less inhibitory to B cell growth. However the optimal dose
is yet to be determined.
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IN VIVO VERSUS EX VIVO B-LYMPHOCYTE PURGING OF PBPC FOR
AUTOLOGOUS TRANSPLANTATION IN B-CELL NHL
Koç, O.N.; Meyerson, H.; Cooper, B.W.; Fox, R.M.; Gerson, S.L.;
Laughlin, M.J.; Simic, A.; Lazarus, H.M. Departments of Medicine and
Pathology, Ireland Cancer Center at CWRU and UHC, Cleveland, OH
We evaluated the safety and efﬁcacy of B-lymphocyte purging of
PBPCs in patients with B-cell NHL undergoing high dose
chemotherapy. We randomized 12 patients to either receive i.v.
Rituximab 375 mg/m2 weekly x 3 just before mobilization (arm A
n=5) or ex vivo purging of mobilized PBPCs using CD34 enrich-
ment device CliniMACS (AmCell, CA) (arm B n=7). In arm B, 7
patients underwent a total of 10 CD34+ cell enrichment proce-
dures. Mean CD34 yield was 62%±17 and the CD34 purity was
93±8 with average CD34+ cell enrichment of 250±198 fold. Total
MNC infused (x 108/kg) was 10.3±6.2 for arm A and 0.05±0.02 for
arm B. The number of CD3+ cells infused at the time of trans-
plantation was signiﬁcantly lower in ex vivo purged arm compared
to the in vivo purged arm (0.01±0.01 vs. 37.4±17.8 x 106/kg).
There was no signiﬁcant difference in the number of CD34+ cells
infused and there were no detectable B cells in either infusate. Fol-
lowing PBPC infusion, median time to neutrophils >500/µl was 9
(range 7-13) days for arm A and 10 (11-17) days for arm B, to
platelets >20.000/µl 13 (8-17) days for arm A and 17 (13-23) days
for arm B and to lymphocytes >500/µl 24 (9-130) days for arm A
and 30 (25-142) days for arm B. CD3+ T-lymphocyte, CD19+ B-
lymphocyte and immunoglobulin levels remained low in all
patients for 3-6 months, although there was only 1 late infectious
complication in arm A and 2 in arm B. Our preliminary data sug-
gest that B-lymphocyte purging of PBPCs by either in vivo Ritux-
imab therapy or ex vivo CD34+ cell enrichment using CliniMACS
device is feasible without signiﬁcant delay in myeloid engraftment.
Effects of these manipulations on lymphoid engraftment and post
transplant infectious complications are being investigated.
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INTERMEDIATE VERSUS STANDARD DOSE OF G-CSF FOR STEM
CELL MOBILISATION IN HEALTHY DONORS FOR ALLOGENEIC
TRANSPLANTATION
Kröger, N.; Renges, H.; Sonnenberg, S.; Krüger, W.; Gutensohn, K.;
Dielschneider, T.; Cortes-Dericks, L.; Zander, A. University Hospital,
Hamburg, Germany
We compared in a retrospective analysis two doses of recombi-
nant human granulocyte stimulating factor (G-CSF) for stem cell
mobilisation in 90 healthy donors for allogeneic stem cell trans-
plantation. Group I (n=46) received 10 µg/kg G-CSF (Filgrastim)
given as 5 µg/kg twice daily, and group II (n=44) received 16
µg/kg, given as 8 µg/kg twice daily with a 12 hour interval. The
groups were well-balanced for age and body-weight. G-CSF
application was performed on an out-patient basis, and leuka-
pheresis was started in all donors on day 5. The most frequent side
effects of G-CSF were bone pain grade I/II, headache grade I/II
and fatigue grade I/II in both groups, whereas grade III of bone
pain, headache and fatigue occurred in the 2 x 8 µg/kg group only.
One serious non-fatal event with non-traumatic spleen rupture
occurred in the 2 x 5 µg/kg group. The CD34+ cell count in the
ﬁrst apheresis of all donors was 5.1 x 106/kg donor weight (range,
1.5-19.3). The CD34+ cell harvest was higher in the 2 x 8 µg/kg
group than in the 2 x 5 µg/kg group (7.1 x 106/kg vs. 4.9 x 106/kg;
p=0.09). The target of collecting > 3.0 x 106 CD34+ cells/kg
donor weight with one apheresis procedure was achieved in 95 %
of group I and in 82 % of group II, respectively. The target of col-
lecting > 5.0 x 106 CD34+ cells/kg in the first apheresis was
achieved in 45 % and 61 %, respectively. Administering G-CSF at
a dosage of 8 µg/kg twice daily leads to a higher CD34+ cell yield
than a dosage of 2 x 5 µg/kg, but is associated with increased toxic-
ity and higher cost.
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EFFECTS OF TRANSITIONAL STORAGE CONTAINERS ON RECOVERY
OF TOTAL CELLS AND PROGENITOR CELLS AFTER THAWING OF
BANKED UMBILICAL CORD BLOOD
Kurtzberg, J.; Waters-Pick, B.; Reese, M.; Avrutsky, S.;
DeOliveira, D. Duke University Medical Center, Durham, NC
Umbilical cord blood, cryopreserved for transplantation, is tra-
ditionally stored submerged in liquid nitrogen (LN) (-190°C)
until selection for transplantation. Three-5 weeks before a sched-
uled transplant, the donor unit is removed from LN, placed in a
dry shipper (-150°C) and transported to the transplant center
(TC), a process that takes 2-4 days. At the TC, the unit is either
maintained in vapor phase (VP) or placed back under LN until the
day of transplant (2-3 weeks later) when it is thawed and infused.
To date, there has been no standardization of methods of storage
after shipment. We investigated whether it would be better to
resubmerge the unit under LN or to store in VP after removal
from LN and shipment. Six cord blood units were collected, vol-
ume reduced and red blood cell depleted, divided into 2 equal
aliquots and cryopreserved under LN in 10% DMSO in 2-com-
partment cryopreservation bags. Three weeks later, each unit was
removed from LN, placed in a dry shipper for 4 days, and then
either placed back under LN or stored in VP. At baseline, before
cryopreservation, immediately upon removal from LN (before
placement in the dry shipper, and 3 weeks later - after storage
under LN or in VP, the units were thawed and assayed for cell
counts, viabilities (trypan blue), CD34 cell content, and clonal
progenitors. Recoveries of total cells and CD34 cells were superi-
or in the units stored in VP as compared to LN. We suggest that
this approach be adopted by transplant centers receiving and stor-
ing banked CBUs for transplantation therapy.
LYMPHOMA/MULTIPLE MYELOMA
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EVALUATION OF LYMPHOMAGENESIS IN THE HIGH-RISK, IMMUNO-
SUPPRESSED EBV-NAÏVE CHILD: ASSESSMENT OF AN EXQUISITLY
SENSITIVE EBV ASSAY
Bonilla, P.J.; Bernard, M.V.; Dunn, S.P.; Krueger, L.J. Alfred I.
duPont Hospital for Children, Wilmington, DE
Β-cell posttransplant lymphoproliferative disorders (PTLD)
encompass a broad spectrum differing from reactive plasmacytic
hyperplasia to monomorphic Β-cell lymphoma. Frank lymphoma
is a major life-threatening complication of transplantation. The
genesis of lymphoma is a multi-step process involving a series of
incompletely defined environmental and genetic interactions.
Two major risk factors are life-long immunosuppression and
Epstein-Barr virus infection. Indeed, the ratio of PTLD in sero-
negative to sero-positive children is approximately 10:1. Using a
robot-assisted 7900HT Sequence Detection System (Applied
Biosystems Inc), a 20 µl PCR assay was developed priming the
DNA polymerase gene. With TaqMan probes, this real-time
analysis is precise for >5 magnitudes and detects 2.3 EBV
genomes/assay. While this is sufﬁcient to monitor the EBV-posi-
tive transplant child, it may not be optimal for the EBV-negative,
highest risk patient. For this reason, we also targeted the internal
repeat region. This semi-quantitative analysis highly increased
sensitivity giving a 10-fold boost (avg. Ct = 21.6+0.2) over the
clinical assay (avg. Ct = 25+0.1). To further increase detection
sensitivity, the concentration of the DNA/assay was varied while
the EBV concentration was held constant (see Table I.). Our cur-
rent results suggest that this combined 30-45 fold increase in the
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detection level of EBV can be still optimized using assiduous
binding and better quenched fluorescent probes. Whether this
level of sensitivity is an early warning system for primary infection
or reactivation of donor latently infected cells remains for the
future.
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SPLIT HIGH DOSE MELPHALAN WITH STEM CELL AND FILGRASTIM
SUPPORT IN PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE THERAPY
Conley, S.1; Reynolds, D.1; Moreb, J.2; Edwards, J.3 1. Halifax Medical
Center, Daytona Beach, FL; 2. University of Florida, Gainesville, FL;
3. Walt Disney Memorial Cancer Institute, Orlando, FL
A common myeloablative chemotherapy regimen for Multiple
Myeloma is Melphalan at 200 mg/m2 given as a single infusion
followed by an autologous stem cell transplant. Patients with sig-
nificant co-morbidities are not eligible for myeloablative treat-
ment which precludes entry into an transplant regimen. The only
other treatment option has been aggressive conventional
chemotherapy with cytokine support. Nonablative high dose Mel-
phalan at 100 mg/m2 with cytokine support has a prolonged pan-
cytopenia period with greater than 25 days to recover granulo-
cytes and platelets back to normal parameters. In order to provide
the same dose intensity of drug with fewer complications we have
enrolled patients in a pilot study to deliver Melphalan at 100
mg/m2 followed by both stem cell and Filgrastim support. Study
objectives are: to determine the feasibility of safely treating
patients with this dose of Melphalan; to observe the toxicities of
the treatment; and evaluate the response rate and time to progres-
sion. Patients able to tolerate a single cycle of treatment with full
recovery were treated with a second cycle with stem cell and Fil-
grastim support. This approach ultimately delivers Melphalan at
200 mg/m2 in a split dose regimen. To date 6 patients have been
enrolled with the intent to treat when possible on an outpatient
basis with hospital admission only for treatment related complica-
tions. The average day of stem cell engraftment to greater than
500 granulocytes/microliter is day +12 following stem cell infusion
and initiation of Filgrastim. Patients were prophylaxed with anti-
bacterial, antiviral, and antifungal oral therapy. To date one
patient has required hospitalization for 3 days for dehydration and
low grade fever. All patients have been able to proceed with the
second cycle of therapy. Response to treatment and time to pro-
gression will be monitored and compared with conventional and
high dose myeloablative therapy given in a single infusion.
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NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANT FOR
MULTIPLE MYELOMA:A FEASIBILITY STUDY
Janakiraman, N.; Chamarthy, U.; Nath, R.; Vial, I.; Green, J.; Fort-
ney, C.; Parikh, D. Henry Ford Hospital, Detroit, MI
Between May, 1999 and October 2001, eleven patients diag-
nosed with multiple myeloma underwent non-myeloablative allo-
geneic stem cell transplant (ASCT). Five males and 6 females with
a median age of 54 years were enrolled on this study. Of the ten
patients with multiple myeloma, 5 had kappa light chain, 3 had
IgG kappa, and 1 each with IgA kappa and IgD lambda. One
patient had extra-medullary plasmacytoma. The most common
induction chemotherapy regimen was VAD. Three of 11 patients
had relapsed after prior autologous BMT. The conditioning regi-
men included fludarabine, anti-thymocyte globulin and 140
mg/m2 of melphalan. Cyclosporin and mycophenolate mofetil
(Cellcept) were used for GVHD prophylaxis. Source of stem cells
were HLA-matched siblings in 10 patients and unrelated donor in
one. Median time to neutrophil engraftment (ANC > 500) was 12
days, with median platelet engraftment (> 20,000/mL) occurring
at day 16. Donor engraftment was 100% by day 45 using VNTR
technique. Nine of nine evaluable patients were in near CR on day
100. Three patients ultimately relapsed: 24 months, 7 months and
4 months, respectively. All relapses were treated with DLI. Grade
III acute GVHD occurred in one patient and five others had
Grade I (skin). Extensive chronic GVHD occurred in 5 of 8 evalu-
able patients. Limited chronic GVHD was documented in only
one patient. Median follow-up is 8 months (range, 1 – 31 months).
There were 3 deaths (ARDS/sepsis, progressive disease, and
myocardial infarction). Conclusion: The moderate dose regimen
used here with allogeneic stem cell transplant (ASCT) is associat-
ed with high response rate and is very well tolerated. Longer fol-
low-up and quality of life studies are needed.
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HIGH INCIDENCE OF CLOSTRIDIUM DIFFICILE IN PATIENTS
WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS PERIPHER-
AL BLOOD STEM CELL TRANSPLANTATION
Restrepo, A.1; Schneider, D.L.2; Restrepo, M.I.1; Litofsky, I.D.1;
Devore, P.E.1; Walsh, T.1,2; Gokmen, E.1,2; Ochoa, L.1,2;
Callander, N.S.1,2; Freytes, C.O.1,2 1. University of Texas Health Sci-
ence Center, San Antonio, TX; 2. South Texas Veterans Health Care
System, San Antonio, TX
Introduction: Patients (pts) with Multiple Myeloma (MM) are
predisposed to infections due to hypogammaglobulinemia and
other immune defects. Clostridium difﬁcile has been implicated in
antibiotic-associated pseudomembranous colitis. The administra-
tion of broad-spectrum antibiotics and anti-neoplastic drugs lead
to an intestinal environment that is conducive to the overgrowth
of C.difﬁcile. Previous studies report a low incidence of C. difﬁcile
associated diarrhea after Autologous Peripheral Blood Stem Cell
Transplantation (APBSCT). Purpose: To determine the frequen-
cy of C. difﬁcile infection during the ﬁrst 30 days after APBSCT
in MM patients. Methods: We retrospectively analyzed 83 con-
secutive patients with stage II and III Multiple myeloma following
APBSCT at our institutions from February 1997 to September
2001. All patients with diarrhea underwent testing using the C.dif-
ﬁcile stool toxin by immunoassay. Other causes of infectious diar-
rhea were excluded. Results: Of the 83 patients, 72 (87%) were
men. Median age was 56 (range 41-78) and 75 (90%)patients had
stage III MM at the time of APBSCT. The most frequent condi-
tioning regimen utilized was melphalan in 55 pts (66%) and busul-
fan-cyclophosphamide in 12 pts (15%). Sixty-seven pts (81%) had
fever after APBSCT. The median duration of neutropenia was 6
days (range 3–11). Patients received infection prophylaxis with
acyclovir, fluoroquinolones and fluconazole. Patients with neu-
tropenic fever were initially treated with a third generation
cephalosporin or beta-lactam/lactamase antibiotics. C. difficile
toxin was detected in 15 pts (18%) during the ﬁrst 30 days after
APBSCT. All patients received and responded to metronidazole
therapy with resolution of diarrhea. Conclusion : C. difﬁcile asso-
ciated diarrhea is frequent in patients with MM during the ﬁrst 30
days after APBSCT when compared to other studies. Multiple
myeloma patients undergoing APBSCT with diarrhea should be
evaluated for C. difficile infection. Better strategies should be
developed to prevent infections in these individuals.
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ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING AN INTENSI-
TY REDUCED REGIMEN WITH FLUDARABINE AND MELPHALAN
RESULTS IN LOW TRANSPLANT RELATED MORTALITY AND LOW
INCIDENCE OF RELAPSE IN MULTIPLE MYELOMA
Rodriguez, T.E.; Simpson, D.R.; Klingemann, H.G. Rush-Presbyter-
ian-St. Luke’s Medical Center, Chicago, IL
High Dose chemotherapy and allogeneic stem cell transplanta-
tion is capable of inducing long term survival in patients with
Multiple Myeloma. Nevertheless, the high transplant related mor-
tality of approximately 25-50% observed in this population limits
the beneﬁts of this treatment modality. We report our experience
in 17 patients with advanced Multiple Myeloma who underwent
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allogeneic stem cell transplantation with an intensity reduced regi-
men consisting of Fludarabine 30 mg/m2 x 3 (D-5 to -3) and Mel-
phalan 80 mg/m2 x 2 (D-2, -1). All patients received G-CSF
(10mg/kg/day x 4) mobilized, 6/6 HLA-matched sibling donor
stem cells. Graft Versus Host Disease prophylaxis consisted of
Cyclosporine and Methotrexate. The median age was 53 years
(range 39-61). Patients received a median stem cell dose infusion
of 3.74 x 106 CD34+ cells/kg (range 2.3-7.55). Results: The
median time for patients to achieve an absolute neutrophil count =
0.5 x 10 9 /L was 13 days. No graft rejection was observed. Of 12
evaluable patients, 11 were ≥ 96% donor T-cell chimeras at day
+100. One patient developed mixed chimerism (93% donor T-
cell) for which quick tapering of Cyclosporine was initiated. Four
patients have died since the initiation of this study. One (5%)
patient died before day +100 from a contaminated platelet transfu-
sion. The other three patients died from disease progression.
With a median follow up of 15 months, the Kaplan Meier proba-
bility of overall survival is 87% and the probability of progression
free survival is 76%. Conclusion: We conclude that an intensity
reduced regimen consisting of Fludarabine and Melphalan is a
suitable preparative regimen for allogeneic transplantation in
patients with advanced Multiple Myeloma, resulting in adequate
engraftment, low incidence of transplant related mortality, and
low incidence of relapse.
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ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
FOR HIGH-RISK NON-HODGKIN’S LYMPHOMA
Seropian, S.; Bahceci, E.; Cooper, D. Yale University, New Haven, CT
The use of PBSC for allogeneic transplantation has been associ-
ated with improved outcome compared to bone marrow in high
risk patients. 28 consecutive NHL patients with high risk features
for regimen related toxicity (RRT) and disease recurrence were
enrolled on clinical protocols utilizing PBSC with a traditional
ablative or modiﬁed conditioning regimen. 21 patients had inter-
mediate/high grade histology, 7 had low grade. Risk factors
included age >50 (n=16), Refractory disease (n=15), failed autolo-
gous transplant (n=11), abnormal organ function (n=2). Median
age of patients receiving ablative or modiﬁed conditioning was 47
and 57 years respectively. Ablative regimens included TBI/CY
(n=8), BEAM (n=7), Bu/Cy (n=1), TBI/TT/Flu (n=1). Eleven
patients received a modified regimen including Fludarabine,
(IV)Busulfan and ATG. Tacrolimus and low dose methotrexate
(5mg/m2 on days +1,+3,+6) were used for GVHD prophylaxis.
PBSC were mobilized from normal donors following Filgrastim
10mcg/kg daily or 6mcg/kg BID for 3-4 days. A median of 5.09 x
10e6 CD34+ cells were infused. Neutrophil and platelet engraft-
ment both occurred at a median of 12 days post transplant. Three
patients died prior to day 100 of RRT (2) and GVHD (1). Grade
II-IV AGVHD occurred in 9/27 and Grade III-IV AGVHD
occurred in 2/27 evaluable patients. Extensive CGVHD occurred
in 21/24 evaluable patients. In 7 patients GVHD appeared to be
the direct result of withdrawal of immunosuppression +/- DLI to
treat persistent or recurrent disease. With a median follow up of
796 days, disease free and overall survival are 57% and 69%.
“Current disease free survival” is 68% as 3/10 patients with recur-
rent/persistent disease post transplant responded to additional
therapy including withdrawal of immunosuppression +/- DLI sug-
gestive of a graft versus lymphoma effect. These results suggest
that the use of PBSC and risk-adjusted conditioning is associated
with improved outcome in this high-risk population.
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LEVELS OF DETECTION OF MYELOMA CELLS BY MOLECULAR METH-
ODS: COMPARISON BETWEEN NESTED PCR AND RQ-PCR WITH THE
TAQ-MAN CYCLER
Togel, F.E.; Kröger, N.; Fehse, B.; Zander, A.R. University-Hospital
Eppendorf, Hamburg, Germany
Multiple myeloma is a malignant disease characterized by inﬁl-
tration of bone marrow sites with plasma cells.Treatment with
high dose therapy results in a high rate of clinical remissions, but
almost all patients ultimately relapse. Clinical staging and detec-
tion of relapse is limited in sensitivity. Therefore, we established
molecular methods using the highly clone-speciﬁc CDR regions
of the immunoglobulin VH locus for sensitive and speciﬁc detec-
tion of residual myeloma cells. Methods: VDJ rearrangements
were identified using a set of VH-primers and a JH primer.
Clone-specific mutations in the CDR regions were identifid by
comparison with germline sequences. Primers were designed
using primer express software. With the nested PCR approach
ﬁrst round ampliﬁcation with the VH family primer and the JH
primer was done followed by second round amplification with
myeloma-speciﬁc primers. The speciﬁc band of exspected size was
visualized on agarose. Taq-Man PCR was performed using a
myeloma-speciﬁc forward primer in combination with a JH-con-
sensus Taq-Man probe and reverse primer. Taq-Man PCR results
were analysed with the applied-biosystems software. Results: Sen-
sitivity was tested using dilutions of myeloma cell lines into nor-
mal mononuclear cells. Nested PCR had a sensitivity of 10-6 and
Taq-Man PCR 10-5. Speciﬁty was determined by testing different
cell lines and patients . With accurate primer design high anneal-
ing temperature no unspecific positive results were observed.
These results were conﬁrmed by follow up of three patients after
dosis reduced conditioning and allogeneic transplant. One patient
in clinical remission is still positive with nested pcr, but tumor-
load as measured by Taq-Man PCR is lower 0,001% myeloma
cells. Conclusion: Molecular methods are a very sensitive and spe-
ciﬁc tool for follow up of myeloma patients after allogeneic bone
marrow transplantation. By using the quantitative approach it is
possible to see kinetics of bone marrow tumor-load which can be
used to guide therapeutic decisions like DLI.
SOLID TUMORS
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HER-2 OVEREXEPRESSION AS PROGNOSTIC FACTOR IN METASTATIC
BREAST CANCER (MBC) PATIENTS TREATED WITH HIGH-DOSE
CHEMOTHERAPY (HDC)
Guarneri, V.1; Bengala, C.1; Orlandini, C.1; Pazzagli, I.1;
Landucci, E.1; Cecchetti, D.2; Campani, D.2; Conte, P.1 1. Division of
Medical Oncology S. Chiara University Hospital,, Pisa, Italy; 2. Divi-
sion of Pathology, S Chiara University Hospital, Pisa, Italy
In breast cancer HER-2 overexpression is associated with worse
prognosis;preliminary data suggest that HDC might overcome the
negative prognostic impact of this factor. To explore this possibil-
ity we have analyzed 32 MBC patients treated with HDC after
induction chemotherapy. 22 pts received a single course of HD
thiotepa+melphalan; 10 pts received also a second course of HD
idarubicin. HER-2 overexpression was determined by IHC using
TAB-250 and Herceptest.At study entry patients characteristics
were as follows: median age 48 yrs (range 28-57);hormone recep-
tor negative in 46% of pts; median number of metastatic sites
3(range 1-5); HER-2 overexpression in 41% of pts. Before HDC
19% of the pts were in complete remission (CR), 69% in partial
remission (PR) and 12% had stable disease (SD).After HDC 47%
of the pts were in CR (conversion rate 34,3%) and 53% in
PR.Median progression free survival (PFS) and overall (OS) were
21.4 months (mo) (95% CI 16.4-26.4) and 48.5 mo (95% CI 28.4-
68.6) respectively.Median PFS of the pts with p-185> and < 70%
were 14.3 mo (95% CI 10-18.5) and 19 mo (95% CI 15-23)
respectively (p=0.05). Median OS were 27.63 mo (95% CI 16.4-
38.8) and 50.3 mo (95% CI 42.6-58.09) for the pts with high and
low HER-2 positivity respectively (p=0.23). According to Her-
ceptest, median PFS of patients with score 3+ and 0-2+ was 11.8
mo (95% CI 7.3-16.4 ) and 19 mo (95% CI 14.25-23.7) respec-
tively (p: 0.01). Median OS was 19.4 mo (95% CI 5.3-33.4) and
50.3 mo (95% CI 35-65.6) in patients with score 3+ and 0-2+
respectively (p: 0.04).Our data shows an increased incidence of
Her -2 overexpressione; moreover Her 2 overexpression is related
to worse PFS and OS, inspite of HDC.
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HIGH-DOSE CHEMOTHERAPY (HDC) WITH BOLUS STAMP V AND
PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) FOR EARLY
STAGE HIGH-RISK PRIMARY BREAST CANCER (HRPBC) IN A COM-
MUNITY-BASED ONCOLOGY NETWORK
Williams, S.; Cuasay, L.; Mandanas, R.; Quiett, K.; McGuirk, J.;
Rifkin, R.; Beveridge, R. US Oncology, Houston, TX
The role of HDC with PBSCT in breast cancer remains contro-
versial. HRPBC has a high recurrence rate after standard adjuvant
therapy. US Oncology’s network of community-based stem cell
transplant programs (21 centers in 16 states) used HDC and trans-
planted 234 HRPBC patients between August 1996 and June
2000. All patients were treated with bolus STAMP V consisting of
Cyclophosphamide 6,000 mg/m2, Thiotepa 500 mg/m2, and Car-
boplatin 800 mg/m2 divided equally over 3 days, followed by stem
cell reinfusion. All patients, except one, were female. Median age
was 47.5 years (range: 27-65). At diagnosis, 179 (76.5%) were
stage II and 55 (23.5%) were stage III; 62.4% were ER or PR pos-
itive. Hematopoietic growth factors were used to accelerate
engraftment. Median time to ANC ≥500 cells/µL was 10 days;
median time to platelet count ≥20,000 cells/µL was 12 days.
Eighty-seven (37.2%) required hospitalization within 28 days
post-transplant. All deaths were due to disease progression or
relapse; two (0.9%) occurred within 100 days. With median fol-
low-up of 23.6 months (range: 0.5-52), 1- and 3-year OS were
95.6% and 85.6%, while 1- and 3-year DFS were 81.5% and
60.8%. There were no significant differences in OS and DFS
according to stage and positive lymph nodes (<10 vs. ≥10). (Table)
HDC with PBSCT can be safely administered to patients with
early stage HRPBC in the community setting. Results of complet-
ed randomized clinical trials are eagerly awaited.
STEM CELL BIOLOGY
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CYCLOSPORINE (CSA) MEDIATED INHIBITION OF P-GLYCOPROTEIN
(P-GP) ACTIVITY IN HEMATOPOIETIC PROGENITOR CELL SUBSETS:
IMPLICATIONS FOR DRUG INTERACTIONS IN THE POST TRANS-
PLANT PERIOD
Donnenberg, V.S.; Griffin, D.L.; Yeager, A.M.; Donnenberg, A.D.
University of Pittsburgh Cancer Institute, Pittsburgh, PA
INTRODUCTION: Hematopoietic engraftment following
stem cell transplantation depends on the proliferation and differ-
entiation of hematopoietic progenitor cells. Even after engraft-
ment, transient depression of peripheral counts is common. Prog-
enitor cells protect themselves from xenobiotics by multiple drug
resistance pumps including ABCG2 and P-gp in the primitive side
population and P-gp in committed hematopoietic progenitor cells.
Allogeneic stem cell transplant recipients are exposed to a variety
of therapeutic agents in the immediate post transplant period,
many of which are substrates for and/or inhibitors of P-gp. In par-
ticular, cyclosporine (CsA) inhibits P-gp in the micromolar range.
METHODS/RESULTS: Since P-gp inhibition could render pro-
genitor cells more susceptible to toxic insults and unanticipated
drug interactions, we evaluated the effects of CsA on CD34+
peripheral blood progenitor cells (PBPC), subsetted on into
CD38+ (more differentiated) and CD38- (less differentiated) cells.
We used a rhodamine 123 (R123) dye efflux assay to measure
basal and substrate induced P-gp activity in the absence and pres-
ence of CsA (5 microM). Neither CD34 subset expressed signiﬁ-
cant basal P-gp activity, as measured by R123 efﬂux in short term
(15’) culture. In the absence of CsA, both subsets evidenced strong
and homogenous substrate-induced activity (measured from 15-
180 minutes in culture). Addition of CsA (5 microM) only partial-
ly inhibited R123 efﬂux in both subsets. In contrast, verapamil (50
microM), a model P-gp inhibitor, blocked dye efflux only in
CD38- CD34+ cells. CONCLUSIONS: The absence of basal
activity is consistent with the absence of substrate-induced P-gp
activation in vivo. Partial blockade by CsA may indicate a CsA
resistant pump or an insufﬁcient CsA dose. Blockade of primitive,
but not differentiated progenitors by verapamil may indicate the
activity of a pump distinct from P-gp and ABCG2 in these cells.
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PLATELET-DERIVED MICROPARTICLES BIND TO HEMATOPOIETIC
STEM/PROGENITOR CELLS AND ENHANCE THEIR ENGRAFTMENT
AFTER TRANSPLANTATION
Janowska, A.1; Majka, M.2; Ratajczak, M.Z.2 1. University of Alberta,
Edmonton, AB, Canada; 2. University of Louisville, Louisville, KY
Since human CD34+ cells as well as murine Sca-1+ hematopoietic
stem/progenitor cells (HSPC) express platelet-activating sialomucin
P-selectin (CD162) and integrin Mac-1 (CD11b/CD18) antigen we
inferred that these cells may interact with platelets. As a result of
this interaction, microparticles derived from platelets (PMPs) could
transfer many platelet antigens (CD41, CD61, CD62, CXCR4,
PAR-1) to the surface of HSPC. To determine the biological signif-
icance of the presence of PMPs on human CD34+ and murine Sca-
1+ cells we initially compared their expression on mobilized periph-
eral blood (mPB)- as well as non-mobilized PB- and bone marrow
(BM)-derived CD34+ cells and then studied the effects of PMPs on
i) proliferation of CD34+ and Sca-1+ cells and ii) adhesion of HSPC
to endothelium and immobilized SDF-1. Finally, we examined the
hematopoietic reconstitution of lethally-irradiated mice transplant-
ed with BM mononuclear cells covered or not covered with PMPs.
We found that PMPs (i) are more numerous on mPB than BM
CD34+ cells, (ii) do not affect the clonogenicity of human and
murine HSPC, and (iii) increase adhesion of these cells to endothe-
lium and immobilized SDF-1. Moreover, murine BM cells that we
covered with PMPs engrafted in lethally-irradiated mice signifi-
cantly faster than those not covered, indicating that PMPs play an
important role in the homing of HSPC. This could explain why in a
clinical setting human mPB HSPC (densely covered with PMPs)
engraft more rapidly compared to BM HSPC, with fewer. Our
ﬁndings indicate a new role for PMPs in stem cell transplantation
and may have clinical implications for optimizing transplantation.
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EXAMINATION OF THE NECESSITY FOR SERIAL BLOOD CULTURES IN
FEBRILE STEM CELL TRANSPLANTATION PATIENTS
Liesveld, J.L.; Hall, D.; Wedow, L.; MacDonald, G.; Hardy, D. Uni-
versity of Rochester Med.Ctr./SMH, Rochester, NY
Fever in stem cell transplant (SCT) patients prompts empiric
antibiotic therapy and obtaining blood cultures to monitor for
presence of bacterial infections. The University of Rochester SCT
unit has a policy that blood cultures are obtained at least once
every 24 hours while the patient remains febrile and at times when
a febrile patient’s clinical condition changes. Given the low overall
frequency of positive blood cultures in our patient populations
(0.084), we examined retrospectively whether changing culture
frequency to every 48 hours might result in cost savings without
compromise of patient safety. The study sample consisted of all
blood cultures obtained on the transplant unit in patients under-
going myeloablative conditioning from January to October, 2000.
Episodes that had only one initial blood culture and no subse-
quent draws were excluded. 124 cultured febrile episodes occurred
with an average length of 4 days. A binary probity analysis
revealed that the result of the initial culture was a good predictor
of the result of the second culture at 24 hours (p-value .0087 and
McFadden R-squared value 0.1017). The probability of the sec-
ond draw being positive when the ﬁrst draw was negative was only
107B B & M T
Poster Presentations - Session II
4.5%. In matched unrelated donor transplants, this probability
rose to 10%. The predictability of the ﬁrst draw on the third (48
hours) result was not accurate. The predictive value of the first
blood culture result, therefore, suggests safety of waiting 48 hours
for a second blood culture draw in febrile autologous and matched
sibling allogeneic transplant patients begun on broad spectrum
antibiotics empirically. Since the cost of each negative blood cul-
ture at our institution is $65.75 (raw materials, laboratory costs,
and nursing times), the policy to perform blood cultures every 48
versus every 24 hours would result in a 50% reduction in the
blood culture budget.
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IDENTIFICATION OF A CANDIDATE HUMAN NEUROHEMATOPOIETIC
STEM-CELL POPULATION
Shih, C.; Weng, Y.; Mamelak, A.; LeBon, T.; Forman, S.J. City of
Hope National Medical Center, Duarte, CA
It was recently reported that transplantation of clonally
derived murine neural stem cells (NSCs) into sublethally irradi-
ated allogeneic hosts lead to a donor-derived hematopoietic
reconstitution. The confirmation of the existence of a common
neurohematopoietic stem cell in human brain will have a signif-
icant impact in stem cell research and in clinical transplanta-
tion. In this study, we have investigated if human NSCs possess
in vivo hematopoietic potential in SCID-hu mice. Our results
demonstrate that human fetal brain tissues contain separate but
overlapping EGF- and FGF-2-responsive NSCs. These human
NSCs express characteristic neural stem/progenitor cell markers
including nestin, and receptors for EGF and FGF-2. These
human NSCs can be maintained and expanded in vitro for many
passages and still retain their self-proliferative and multilineage
potential for neurons, astrocytes, and oligodendrocytes. Our
first approach to determine the hematopoietic potential of
human NSCs was to culture the human NSCs in a murine stro-
mal co-culture system which has been previously developed in
our laboratory and supports ex vivo human hematopoietic stem
cell expansion. Results from in vitro co-cultures did not show
detectable human hematopoietic cells. These results suggest
that this stromal co-culture system is not sufficient to support
differentiation of human NSCs into hematopoietic cells in
vitro. The SCID-hu mouse model was then utilized to deter-
mine if a human bone marrow (BM) microenvironment is
required for hematopoietic differentiation of human NSCs.
One million human NSCs were injected directly into each
human graft, including thymus and bone fragment, in SCID-hu
mice, and NSCs-derived hematopoietic cells (HLA-MA2.1-pos-
itive) in those injected human grafts were analyzed 4 months
after NSC injection. Our results demonstrate that cultured
human NSCs do possess in vivo hematopoietic potential, and
that differentiation of cultured human NSCs into hematopoietic




AMBISOME® PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENE-
IC STEM CELL TRANSPLANTATION (ALLOSCT)
Cairo, M.S.; DiNatale, J.; Harrison, L.; Wolownik, K.;
Bessmertny, O.; Del Toro, G.; Bradley, B.; Yamashiro, D.; Garvin, J.
Children’s Hospital of New York Presbyterian, Columbia University,
New York, NY
Walsh et al (NEJM 1999; 340: 764-71) reported a randomized,
multi-center trial comparing liposomal amphotericin B (AmBi-
some®) (AmB) with amphoB in patients that developed fever
and neutropenia (45% BMT recipients) but not given prophylac-
tically, and demonstrated significantly fewer breakthrough fun-
gal infections with AmB vs. amphoB (3.2 vs. 7.8%)(p<0.009). We
initiated a pilot study to determine the safety and efficacy of
AmB given prophylactically to AlloSCT recipients. Twelve
AlloSCT patients were given AmB prophylactically (3 mg/kg) IV
once a day, day 0 to day +100. Median age of the recipients was
11.5 years (range 2-21 years), 5 F and 7 M; 3 ALL (2 CR2, 1
CR3), 2 HD NED, 1 AA, 1 SS, 1 relapsed AML, 1 refractory
Hodgkin’s, 1 lymphoblastic lymphoma, 1 CML -CP, and 1
WAS. Donor types were UCB (2:5/6; 5:4/6), 3 6/6 HLA
matched related PBSC, and 2 BM. All patients received
FK506/MMF GVHD prophylaxis. Only 1/12 patients required
premedication with Tylenol® and Benedry®. AmB was well tol-
erated with 2 pts experiencing grade 3 hypokalemia, 2 with grade
3 creatinine and 1 with grade 3 hypotension. There have been
no (0%) documented emergent systemic fungal infections. 3/12
patients died (1 grade IV GVHD, 1 PD, 1 respiratory failure 2°
to ARDS) and no evidence of fungal infections on autopsy.
These preliminary results suggest that AmB may be given safely
prophylactically and may be effective in the prevention of emer-
gent systemic fungal infections in related and unrelated AlloSCT
recipients. Larger studies are required to determine the overall
safety of this approach and its potential efficacy compared to
other approaches.
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USE OF A SUPPORTIVE CARE TEAM FOR SCREENING AND PREEMP-
TIVE INTERVENTION: PRETREATMENT LEVELS OF DISTRESS,
FATIGUE, PAIN, NUTRITIONAL RISK, AND SEXUAL CONCERNS
AMONG STEM CELL TRANSPLANT PATIENTS
Coleman, E.; Grifﬁth, K.; Sherman, A.C.; Cromer, J.; Simonton, S.;
Latif, U.; Hine, J.; Farley, H.; Garcia, R.; Knight, M.; Krishnan, S.;
Anaissie, E.J. University of Arkansas for Medical Sciences, Little Rock, AR
Stem cell transplant (SCT) patients may be burdened by exten-
sive physical symptoms and quality-of-life impairments. These
difficulties may be evident even prior to aggressive treatment;
often they are overlooked or are managed episodically. Recently
we pilot-tested an interdisciplinary supportive care program
designed to facilitate early screening and preemptive treatment.
This pilot program was developed to identify patients at risk dur-
ing their initial work-up for SCT, to reduce subsequent complica-
tions. 61 patients were assessed during their initial clinic evalua-
tion. Average age was 57.0; 63.9% were male, and 91.8% were
white. Most patients had multiple myeloma (85.3%). Average
time since diagnosis was 7.4 months, and extent of prior treat-
ment varied widely. Clinical interviews were conducted by a nurse
practitioner, supplemented by validated measures of distress
(Hospital Anxiety and Depression Scale), fatigue (POMS-
Fatigue), pain (Brief Pain Inventory), nutritional risk (PG-SGA),
sexual difﬁculties (rating scales), and quality-of-life (SF-12). The
prevalence of symptoms was high across multiple spheres of func-
tioning. The majority (58.1%) scored substantially below national
norms for physical dimensions of quality-of-life (SF-12 PCS).
Nutritional deﬁcits were evident for 59.7%. Forty-seven percent
exceeded cut-offs for fatigue. Thirty-one percent of patients
reported elevated levels of distress; 27.9% scored within the
“probable case” range for anxiety and as did 24.6% for depression.
Average pain intensity was moderate or greater for 35.9% of
patients; it was severe for 13.2%. Similar percentages reported
that day-to-day life was at least moderately (36.4%) or severely
(18.2%) impaired due to pain. Difficulties with body image and
sexual functioning were noted by 35.6%. Findings suggest that a
substantial proportion of patients would beneﬁt from supportive
care screening early in the course of treatment, prior to beginning
conditioning regimens and transplant. Early, systematic screening
for physical and emotional symptoms appears to be feasible and
may contribute to improved care.
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ORAL GLUTAMINE TO IMPROVE NUTRITION AND REDUCE GAS-
TROINTESTINAL TOXICITY IN STEM CELL TRANSPLANTATION
Conley, S.; Carbley, R.; Reynolds, D.; Alexander, J.; Alexander, C.;
Sorathia, A.; Luwisch, E. Halifax Medical Center, Daytona Beach, FL
The maxi-ICE induction transplant regimen with Ifosfamide,
Carboplatin and Etoposide induces severe documented gas-
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trointestinal toxicity requiring total parenteral nutrition. From
1996 - 1999 ten patients who received maxi-ICE were enrolled
in an institutional study to receive oral glutamine at 0.5
mg/kg/day in divided doses not to exceed a total dose of 40
mg/day beginning the day of high dose chemotherapy and
continued until oral intake could not be accomplished due to
mucositis. Outcomes were initially compared to published ret-
rospective data describing the toxicities observed with the
same maxi-ICE regimen as reported by the Moffitt transplant
group in Tampa. In comparing the maximum recorded toxicity
scores for mucositis and enteritis the Halifax group appeared
to score higher than the Moffitt data base. However because of
the differences in subjective scoring between two transplant
teams using the WHO scales this was judged to be an unreli-
able comparison. Using the Halifax data alone the number of
continuous days of mucositis was consistently decreased as the
maximum cumulative recorded doses of glutamine taken
increased. In addition the days of TPN required directly cor-
related with the total cumulative dose of oral glutamine taken
with statistical significance using linear regression ( P = 0.046
). Previous published reports of oral glutamine to reduce GI
toxicity in the transplant population have been conflicting.
This may be due to a combination of patients treated with dif-
ferent regimens many of which induce only mild mucositis.
Other glutamine studies have also employed lesser doses of
oral glutamine compared to that used in the study reported
here. The only statistical findings in the current study relate to
more benefit as the amount of oral glutamine is increased.
However this appears to be a very cost effective supportive
care method to reduce morbidity in regimens that induce sig-
nificant gastrointestinal toxicity.
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COMPARISON OF TREATMENT EFFECTS BETWEEN BETADINE/NYS-
TATIN AND GM-CSF ORAL GARGLINGS AMONG PATIENTS WITH
CHEMOTHERAPY INDUCED STOMATITIS
Hong, J.; Kwon, I.; Huh, S.; Jung, M.; Park, C. Samsung Medical
Center, Seoul, South Korea
- purpose : This study was conducted to compare treatment
effects between betadine/nystatin and GM-CSF oral garglings
among patients with chemotherapy induced stomatitis, grade
2 or higher. - method : From May 2000 to September 2001,
30 subjects with chemotherapy induced stomatitis, grade 2 or
higher by Nicolatou method, among BMT, hematologic
malignancy and other solid cancer patients were recruited. 19
subjects were treated by GM-CSF solution (400ug GM-CSF +
40ml normal saline, 4 times a day) and 11 subjects were treat-
ed by conventional betadine/nystatin solution. All subjects
were allocated conveniently. - results : There were no signifi-
cant differences of age, sex, disease conditions, treatment
types, smoking habit, oral hygiene and ECOG score between
two groups. The duration from starting date of treatment to
fully recovered date were not different between two
groups(GM-CSF group was 8.21days and betadine/nystatin
group was 9.7days). But in 10days after treatment, GM-CSF
group showed better effect curve than betadine/nystatin group
by using survival data analysis, and in the aspect of effecting
point, GM-CSF group revealed faster than betadine/nystatin
group, by 6 days grossly, and by 4 days functionally. The
mean numbers of ANC at 2nd day from treatment were
341/ul and 502/ul, and at 6th day, 1,350/ul and 1,342/ul, of
each GM-CSF group and betadine/nystatin group, but no sig-
nificant difference was found by using mixed model analysis. -
conclusion : Although there were no enough statistically sig-
nificant differences between GM-CSF and betadine/nystatin
groups, GM-CSF treatment could be strongly recommended
as a treatment of choice of chemotherapy induced stomatitis,
because GM-CSF treatment showed faster effect than beta-
dine/nystatin treatment.
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A MULTICENTER, RETROSPECTIVE STUDY OF AMPHOTERICIN B-
INDUCED NEPHROTOXICITY IN PEDIATRIC ALLOGENEIC
HEMATOPOIETIC PROGENITOR CELL TRANSPLANT (HPCT) RECIPI-
ENTS WITH INVASIVE FUNGAL INFECTIONS (IFI)
Kletzel, M.1; Chan, K.2; Kapoor, N.3; Seibel, N.L.4; Sandler, E.S.5;
Fleck, P.R.6; Blatt, J.7; Bunin, N.8; Goldman, F.D.9 1. Children’s Memo-
rial Medical Center, Chicago, IL; 2. University of Texas M.D. Anderson
Cancer Center, Houston, TX; 3. Children’s Hospital Los Angeles, Los
Angeles, CA; 4. Children’s National Medical Center, Washington, DC;
5. Nemours Children’s Clinic, Jacksonville, FL; 6. Cincinnati Transplant
Institute, Cincinnati, OH; 7. University of North Carolina at Chapel
Hill, Chapel Hill, NC; 8. Children’s Hospital of Philadelphia, Philadel-
phia, PA; 9. University of Iowa Hospitals & Clinics, Iowa City, IA
Pediatric allo-HPCT recipients are at high risk for IFI, and
Amphotericin B (AMB) is the gold standard of therapy. Limited
data is available regarding patterns of AMB-induced nephrotoxici-
ty in these patients. A multicenter, retrospective chart review of 58
pediatric HPCT recipients treated with AMB between 1995-2000
for proven or probable IFI was conducted in 8 centers. Twenty-
four patients were initiated on CAB (mean dose 0.71±0.34
mg/kg/day) and 34 were initiated on LIPID (mean dose 4.0±2.0
mg/kg/day). There were no significant differences in baseline
demographics between the two treatment groups. Following initi-
ation, 67% of CAB patients required conversion to a LIPID for-
mulation, while 18% of patients initiated on LIPID were convert-
ed to another LIPID (p=0.001). Nephorotoxicity accounted for
81% of CAB patient conversions. The ﬁgure shows the mean per-
cent change in SCr from baseline over time in both initial treat-
ment groups, which was signiﬁcantly less in children who received
LIPID in the first two weeks of therapy (p<0.05). SCr changes
from weeks 3-4 were not significant because most remaining
patients had switched to LIPID* (median 3.5 days). Only 3/24
(13%) patients started on CAB remained on initial therapy at
week 4, compared to 25/34 (74%) patients started on LIPID.
Insert ﬁgure here Conclusion: Initiating patients on CAB therapy
results in the majority being switched to a LIPID formulation due
to nephrotoxicity. Treatment may be better tolerated and admin-
istered for a longer duration if patients are initiated on LIPID
since their SCr changes over time do not increase as rapidly as
patients initiated on CAB.
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SURVEILLANCE BLOOD CULTURES PERMIT EARLY DETECTION OF
POTENTIALLY SERIOUS BLOODSTREAM INFECTIONS IN ASYMPTO-
MATIC OUTPATIENTS WITH GRAFT-VERSUS-HOST DISEASE
Langston, A.A.; Teagarden, D.; Mossavi-Sai, S.; Wright, L.; Redei, I.;
Lonial, S.; Waller, E.K.; Nolte, F.S.; Somani, J. Emory University
School of Medicine, Atlanta, GA
The antipyretic effect of corticosteroids may confound detection of
infections, which are the leading cause of mortality among pts with
graft-versus-host disease (GVHD). At our institution, we obtain reg-
ular surveillance blood cultures on all pts receiving corticosteroid
therapy for GVHD. We examined the yield and microbiology of out-
patient surveillance cultures by retrospective study of 33 consecutive
pts transplanted between 1/99 and 4/01 who developed acute (grades
II-IV) and/or chronic extensive GVHD after matched sibling (n=23),
109B B & M T
Poster Presentations - Session II
unrelated (n=8), or mismatched family donor allografts (n=2). GVHD
sites included skin (22 pts), GI (20 pts), liver (1 pt), and polyserositis
(2 pts). Surveillance cultures, drawn from an indwelling catheter,
began at a median of 49 days post-transplant. Cultures obtained from
febrile (>38C) pts were excluded. Coagulase negative staphylococcus,
diphtheroids (except Corynebacterium JK), and micrococcus were
considered contaminants unless isolated from consecutive cultures.
Other organisms were considered signiﬁcant if isolated from any
blood culture. Using this deﬁnition, 32 separate bloodstream infec-
tion episodes were identiﬁed from cultures drawn at 605 clinic visits
(5% yield); this represented 53 (4.6%) of 1149 individual cultures.
Eight episodes (25%) were polymicrobial. Isolates included 20 gram
positive bacteria, 12 enteric and 6 environmental gram negatives, and
1 yeast (Candida albicans). Positive cultures occurred in 15 of the 33
pts; mean prednisone dose was 50 mg/day (range 16-120) at the time
of positive cultures. In univariate analyses, positive cultures were asso-
ciated with longer duration of prednisone therapy (p=0.01), and sec-
ondary therapy for refractory GVHD (p=0.04). Presence of skin
GVHD was associated with a reduced likelihood of positive cultures
in univariate (p=0.02) and multivariate analyses (p=0.046). All
episodes were successfully treated with systemic antibiotics. These
data indicate that occult bloodstream infections occur with signiﬁcant
frequency in GVHD pts receiving corticosteroid therapy, and sup-
port the practice of surveillance blood cultures in this population.
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COMBINATION GANCICLOVIR AND FOSCARNET TREATMENT OF
CYTOMEGALOVIRUS (CMV) AFTER ALLOGENEIC TRANSPLANT FOR
PATIENTS FAILING SINGLE AGENT THERAPY
Morris, J.D.1; Landers, R.1; Saccente, C.S.1; Arzoumanian, V.2; Mor-
ris, C.L.2 1. Arkansas Children’s Hospital, Little Rock, AR; 2. Univer-
sity of Arkansas for Medical Sciences, Little Rock, AR
We treated 4 patients with hematological malignancies who
failed single agent therapy for CMV following allogeneic stem
cell transplant, 2 with reactivation and 2 with CMV colitis,
with combination ganciclovir and foscarnet therapy. Onset of
CMV reactivation occurred on day 40 and 44 in 2 patients and
CMV colitis was diagnosed on day 91 and 100 in 2 patients.
Three patients had graft versus host disease (GVHD) at the
time of CMV reactivation (n=1) with skin GVHD or CMV
colitis (n=2) with gut GVHD, and 1 patient had no GVHD.
Patients were initially treated with standard induction doses of
ganciclovir (5mg/kg i.v. Q12H, n=3) or foscarnet (100mg/kg
i.v. Q12H, n=1) for 9 to 21 days. Combination therapy was ini-
tiated when treatment failure was documented by rising CMV
peripheral blood antigen level (n=1) after 9 days, persistent
fever after 13 days of ganciclovir induction therapy (n=1), or by
persistence of symptoms of colitis and CMV inclusions on
biopsy of colonic mucosa after 17 to 49 days of treatment (n=2).
All 4 patients were symptomatic with CMV-induced fever (n=2)
or colitis (n=2) at the time combination therapy was initiated.
Patients cleared CMV antigen (n=1), fever (n=1), or colitis (1
biopsy proven and 1 by symptoms) within 5 to 20 days of com-
bination therapy. No significant hematological or renal dys-
function was seen with combination therapy. Combination
therapy with ganciclovir and foscarnet is a promising treatment
for patients failing single agent therapy and warrants a prospec-
tive trial.
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EFFECTS OF HIGH DOSE CHEMOTHERAPY ON SYSTOLIC CARDIAC
FUNCTION AS MEASURED BY LEFT VENTRICULAR EJECTION FRAC-
TION (LVEF)
Nayak, S.; Shikhman, S.; Garner, P.; Dorr, S.; Akhtar, A.; Momin, F.
Oakwood Hospital, Dearborn, MI
Purpose: To study the effects of high dose chemotherapy
(HDCT) on LVEF in patients undergoing auto and allo stem cell
transpalntation. Methods. Our protocols require assessment of
LVEF pre HDCT and 100 days post HDCT. Pre HDCT LVEF
of < 40% excludes patients from HDCT protocols. Cardiac func-
tion of 42 autologous and 11 allograft recipents was studied pre
and 100 days post HDCT. The median age was 53 yrs (27 - 72
yr). Male/Female ratio was 19/34. Standard HDCT regimens
included STAMP V, BU/CY2, BAC, CVB, Melphalan
200mg/m2. Sixteen had breast cancer, 35 had hematological
malignancies and 2 had ovarian cancer. Cardiac funtion was
assessed by 2D Echocardiograms in 33 patients, MUGA in 16
patients and by both in 4. Results: None of the patients had any
symptom of CHF post HDCT. None developed a pericardial
effusion. The median pre HDCT LVEF was 55% for the entire
group (44% to 74%). The median post LVEF was also 55% (40%
to 63%). An asymptomatic reduction in LVEF was observed in
15/53 patients (28.3%). In 3/15 the reduction was > 10%. In 9 the
reduction was >5% and in 3 the reduction was < 5%. In these 12
patients who had a reduction in LVEF of >10% and >5% 5
received Melphalan alone and 7 received Cytoxan at 120 mg/kg. A
pre HDCT LVEF < 55% was observed in 17 patients. There was
no change post HDCT in 11 of these 17 patients. The post
HDCT LVEF reduced by < 5% in 4 and >5% in 2. Again none of
these patients was symptomatic. Conclusion: None of our HDCT
patients developed cardiac symptoms upto 100 days post HDCT.
Cytoxan 120 mg/kg and Melphalan 200 mg/m2 resulted in aymp-
tomatic reductions of LVEF of between 5 and > 10% 100 days
post HDCT.
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COMPARISON OF COMPLICATIONS AND LONGEVITY OF HICKMAN
AND NEOSTAR CATHETERS IN STEM CELL TRANSPLANT RECIPIENTS
Pai, A.; Garner, P.; Dorr, S.; Akhtar, A.; Momin, F. Oakwood Hospi-
tal, Dearborn, MI
Purpose: To prospectively study the complications and
longevity of tunneled Hickman and Neostar Catheters in auto,
allo stem cell recipients and leukemic patients undergoing
chemotherapy. Methods: Fifty Neostar and 38 Hickman
catheters were studied. Neostar catheters can be used for stem
cell collection and therefore were prefered in autografts. The
wider bore Neostar catheter was inserted in autografts prior
to stem cell mobilization and maintained through apheresis
and the transplant course. Hickman catheters were used for
allografts and patients undergoing chemotherapy for
leukemia. All catheters were surgically inserted and subcuta-
neously tunneled in the OR. Both types of catheters were
removed when the patient became transfusion independent
and did not need IV infuaions. Indications for premature
catheter removal were: a)catheter malfunction,
b)Fungemia/gram -ve bacteremia, c) persistent bacteremia on
antibiotics, d)tunnel infection, e) DVT and f)Luminal occlu-
sions that could not be lysed by t-PA. All patients received
oral quinolone and fluconazole for gut decontamination.
Results: There were no gram negative or fungal infections in
any patient. Gram+ bactermia and tunnel infection was signif-
icantly greater in Neostar group (40% and 4%) vs 30% and
0% in Hickman group. The median duration of Neostar and
Hickman catheters were 45 days (9 - 170) and 75 days (19 -
78) days respectively. Premature removal of Neostar due to
infection was 18% compared to 9.4% in Hickman group.
Detailed results are shown in the table below, Conclusion: In
our experience wide bore Neostar Catheters are associated
with more infectious complications and have a shorter
longevity compared to Hickman catheters. Intraluminal occlu-
sions leading to premature removal are more frequent with
Hickman catheters. Venous thrombosis occurred equally in
both groups.
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LOW DOSE DOPAMINE/HEPARIN FOR THE PRE-EMPTIVE TREAT-
MENT OF VENO-OCCLUSIVE DISEASE OF THE LIVER IN PATIENTS
RECEIVING BUSULFAN/CYCLOPHOSPHAMIDE AND ALLOGENEIC OR
AUTOLOGOUS STEM CELL TRANSPLANTATION
Sivasubramaniam, V.; Dodds, S.; Lyman, G.H.; Hiemenz, J.;
Maloy, B.; Morgalis, M.; Cirenza, E.; Ballester, O. Albany Medical
Center, Albany, NY
Veno-occlusive disease (VOD) of the liver is recognized as a
common complication of high-dose therapy and a major cause
of morbidity and mortality. Various prophylactic approaches
have suggested that the incidence of VOD could be decreased
(from 40% to 15%) but this would require treating the entire
patient population. We report here a prospective study evaluat-
ing the pre-emptive treatment of VOD, at the earliest
detectable elevation of serum bilirubin and prior to the estab-
lishment of the full clinical syndrome. The protocol called for
administration of dopamine at 2µg/kg/min and heparin infusion
at 100 units/hour triggered by an elevation of total serum
bilirubin ≥1.2 mg/dL within the first 20 days post transplant.
From August 1994 -August 2001, 37 consecutive patients
received Bu/Cy (Busulfan 16 mg/kg po over 4 days and
cyclophosphamide 120 mg/m2 over 2 days) followed by allo-
geneic (n=16) or autologous (n=21) stem cell rescue. Diagnosis
included AML(n=10), NHL(n=9), HD(n=6), myeloma(n=5),
others(n=7). The protocol was activated in 12 patients who met
criteria on day + 6.5 (median) with a mean total bilirubin of
1.68 mg/dL at initiation of protocol. In these patients the mean
peak value of total bilirubin rose to 3.23 mg/dL on day + 11
(median). Of these 12 patients 2 met criteria for VOD
(McDonald, Hepatology, 1984). There was one episode of gas-
trointestinal bleed in the treated group during the first 100
days post-transplant. The non-treated group had one episode
of hematuria. Overall, transplant related mortality during the
first 100 days post transplant was 2.7% (1 death related to
recurrence of AML). There were no deaths due to VOD or
bleeding complications. In conclusion, our study reveals that
pre-emptive treatment with heparin and dopamine instituted in
32% of the patients resulted in a low VOD incidence of 5.4%.
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FACTORS ASSOCIATED WITH INCREASED HOSPITAL COSTS IN
PATIENTS TREATED WITH LIPID-BASED ANTI-FUNGAL THERAPY
Tong, K.B.1; Greenberg, R.N.2; Cagnoni, P.J.3; Wingard, J.R.4;
Prendergast, M.M.5 1. Quorum Consulting, Inc., San Francisco, CA;
2. University of Kentucky, Lexington, KY; 3. University of Colorado
Health Sciences Center, Denver, CO; 4. University of Florida Col-
lege of Medicine, Gainesville, FL; 5. Fujisawa Healthcare, Inc.,
Deerfield, IL
BACKGROUND. A randomized, double-blind, comparative
multi-center trial was conducted to compare liposomal ampho-
tericin B (L-AmB) and amphotericin B lipid complex (ABLC) for
empirical anti-fungal therapy. The doses for L-AmB were 3
mg/kg per day and 5 mg/kg per day, and the dose for ABLC was
5 mg/kg per day. L-AmB was found to have a superior safety
profile in febrile neutropenic patients compared to ABLC.
Nephrotoxicity was significantly higher in ABLC patients.
OBJECTIVES. The purpose of this analysis is to determine if
other factors contribute to increased hospital costs and length of
stay. METHODS. A retrospective analysis of 89 patients
enrolled in the clinical study was performed to assess hospital
costs and length of stay following the start of empirical anti-fun-
gal therapy. Bivariate and multivariate regressions were per-
formed to identify variables most likely to affect hospital costs
and length of stay. RESULTS. Allogeneic BMT status, days of
treatment, doubling of baseline creatinine, and dialysis were
found to be predictive both of increased hospital costs and
length of stay. Length of stay and number of concomitant
nephrotoxic agents also were found to affect hospital costs.
CONCLUSIONS. Overall, risk factors and clinical outcomes
associated with nephrotoxicity increased hospital costs and
length of stay in patients treated empirically with lipid-based
anti-fungal agents. In conclusion, the determination of the opti-
mal lipid-based agent for empirical anti-fungal therapy should
incorporate both patient-specific risk factors and product-specif-
ic outcomes.
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ACUTE RENAL DYSFUNCTION ASSOCIATED WITH ANTITYHMOCYTE
GLOBULIN IN THE CONDITIONING FOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Voltarelli, J.; Stracieri, A.; Coutinho, M.; Paton, E.; Almeida, K.;
Vieira, O.; Dantas, M. BMT Unit, Hospital das Clinicas of Ribeirão
Preto, University of São Paulo, Ribeirão Preto, Brazil
We report two cases of acute renal dysfunction associated
with the infusion of horse antithymocyte globulin (Lym-
phoglobuline, Sangstat, France) in the conditioning for stem
cell transplantation. The first patient (26 y old, male) had
severe aplastic anemia and was conditioned with cyclophos-
famide (50mg/kg x4) and ATG (30 mg/kg x3). Hydrocortisone
and dexchlorpheniramine were given before ATG. During the
first dose, the patient developed fever, shaking, skin rash,
abdominal pain, vomiting, hypotension (8 x 4 mmHg) and low
urinary output. He was treated with steroids and the infusion
was completed. In the next day, serum creatinine rose from 1.2
to 2.3 mg/dl, arterial tension dropped to 8 x 5, urinary output
decreased and he was treated with dopamine and IV fluids.
ATG was witheld and given in the next day producing fever
and shaking. He was treated with hydrocortisone, the rest of
the 2nd dose and the 3rd dose were given at slower rate with-
out reactions. The second patient (26 y, m) received an autolo-
gous peripheral blood stem cell transplantation for lupus
nephritis. Planned conditioning was CY 200 mg/kg plus ATG
(15 mg/kg x6). During the 1st dose of ATG the patient devel-
oped skin rash, shaking and arterial hypertension (19 x 12
mmHg). Infusion was completed at slower rate. Creatinine rose
from 1.7 to 2.1 and after the 2nd. dose of ATG blood pressure
increased and urine output decreased until anuria. Creatinine
rose to 4.5, arterial tension to 17 x 13, hemodialysis was per-
formed and the CY dose was completed, but no further ATG
was given. Renal function improved gradually and the patient
was discharged on D+32. We hypothesize that release of
cytokines by ATG caused renal dysfunction in our patients. We
are aware of only one other similar case reported at Am J Kidn
Dis 34:1155, 1999.
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A MULTICENTER, RETROSPECTIVE STUDY OF AMPHOTERICIN B
(AMB)-INDUCED NEPHROTOXICITY IN ADULT ALLOGENEIC
HEMATOPOIETIC PROGENITOR CELL TRANSPLANT (HPCT) RECIPI-
ENTS WITH INVASIVE FUNGAL INFECTIONS (IFI)
Waller, E.K.1; Miller, C.B.2; Chao, N.J.3; Annaissie, E.J.4;
Fleck, P.R.5; Klingemann, H.6; Fruchtman, S.7; McGuirk, J.8;
Cagnoni, P.J.9; McSweeney, P.9 1. Emory University, Atlanta, GA;
2. Johns Hopkins University, Baltimore, MD; 3. Duke University
Medical Center, Durham, NC; 4. University of Arkansas Medical
School, Little Rock, AR; 5. Cincinnati Transplant Institute, Cincinnati,
OH; 6. Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL;
7. Mount Sinai Medical Center, New York, NY; 8. Oncology & Hema-
tology Associates of Kansas City, Kansas City, MO; 9. University of Col-
orado Health Sciences Center, Denver, CO
AMB remains the drug of choice for IFI in adult HPCT
recipients. Lipid AMB formulations (LIPID) are less nephro-
toxic than conventional AMB (CAB), but there is still a contro-
versy regarding when LIPID therapy should be initiated. A
multicenter, retrospective chart review of 87 adult allogeneic
HPCT recipients was conducted in 8 centers between 1995-
2000. Thirty-three patients were intiated on CAB (mean dose
0.7±0.3 mg/kg/day) and 54 were initiated on LIPID (mean dose
4.9±1.9 mg/kg/day) for proven or possible IFI. There were no
significant differences in baseline demographics between the
two treatment groups, however LIPID patients had a signifi-
cantly higher mean baseline serum creatinine (SCr) compared
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to CAB patients (1.11±0.69 vs. 1.44±0.92 mg/dL, p<0.01). Fol-
lowing initiation of therapy, 64% of CAB patients required
conversion to a LIPID (median of 4 days), while 22% of
patients initiated on a LIPID were converted to another LIPID
(p<0.001). Nephrotoxicity accounted for 81% of CAB patient
conversions. The figure below shows significantly more
nephrotoxicity among patients initiated on CAB then subse-
quently switched to LIPID compared to patients initially treat-
ed with LIPID (p<0.05 comparing percent change in SCr from
week 1 to week 4). Significantly more patients who were con-
verted from CAB to LIPID experienced a doubling in SCr com-
pared to patients initially treated with LIPID (p=0.04). 6/33
(18%) patients started on CAB remained on initial therapy at
week 4, compared to 29/54 (54%) patients who received initial
therapy with LIPID. Insert Figure here Conclusion: Initial
therapy with CAB in HPCT recipients resulted in the majority
being switched to LIPID due to nephrotoxicity. The strategy of
starting CAB and switching to LIPID did not result in an
improvement in nephrotoxicity compared to initiating patients
on LIPID (p<0.05). Initiating antifungal therapy with LIPID
limits nephrotoxicity in allogeneic HPCT recipients.
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GRANISETRON VERSUS ONDANSETRON IN THE PREVENTION OF
NAUSEA AND VOMITING IN BONE MARROW TRANSPLANT PATIENTS:
RESULTS OF A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED TRIAL
Walsh, T.L.1,2; Valley, A.W.1,2; Holle, L.M.1,2; Morris, A.K.1,2; Callan-
der, N.S.1,2; Freytes, C.1,2; Bradshaw, P.2; Clark, G.2 1. South Texas
Veterans Health Care System, Audie L. Murphy Division, San Antonio,
TX; 2. University of Texas Health Science Center, San Antonio, TX
The 5HT3 antagonists represent a significant advance in the
prevention of acute nausea and vomiting from highly emetogenic
chemotherapy. The majority of conditioning regimens for bone
marrow transplantation(BMT) are highly emetogenic and 5HT3
antagonists, in combination with other antiemetics, have been
incorporated as the standard of care for prevention of nausea and
vomiting in this setting. At our institution, the standard prophy-
lactic antiemetic regimen at the time of study initiation included
intravenous ondansetron as the chosen 5HT3 antagonist. Howev-
er, with the advent of granisetron, another 5HT3 antagonist, we
sought to determine if there were any differences in efficacy or
toxicity between these 2 agents during conditioning therapy for
autologous BMT. A total of 110 patients were randomized(96
evaluable) to receive either ondansetron 0.15 mg/kg IV Q8H or
granisetron 10 mcg/kg IV QD. Additionally, both treatment
groups received dexamethasone 10 mg IV QD and lorazepam 1
mg IV Q8H. Antiemetic prophylaxis was continued until 24 hours
after completion of chemotherapy. Nausea and distress were
measured subjectively with visual analog scales and emetic
episodes were quantified. Patient demographics and risk factors
for nausea/vomiting were similar between treatment groups. In
the granisetron group(n=46), 48% experienced none-mild nausea
and 52% experienced moderate-severe nausea. The ondansetron
patients(n=50) had similar results with a 50% incidence in each
category(p=0.841; Fisher’s exact test). The median number of
emetic episodes for granisetron and ondansetron was 3(range 0-
15) and 1(range 0-9) respectively, (p=0.228; Wilcoxon rank-sum).
The overall incidence of adverse effects were also similar for
ondansetron and granisetron(p = 0.294; Wilcoxon rank-sum), and
no patient prematurely discontinued the study because of severe
toxicities. This study conﬁrms that ondansetron and granisetron
are equally effective and safe in the prevention of acute nausea and
vomiting associated with conditioning therapy for autologous
BMT. The agent of choice should be based on institutional cost.
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BUGSLUG: ANALYSIS OF EPIDEMIOLOGY AND DRUG SUSCEPTIBILITY
DATA UTILIZING A RELATIONAL DATABASE
White, M.2; Lyons, E.2; Mann, L.1; Pineiro, L.1,2; Vance, E.1,2;
Berryman, B.1,2; Fay, J.1,2; Agura, E.1,2 1. Baylor University Medical
Center, Dallas, TX; 2. Baylor-Sammons Cancer Center, TOPA, Dal-
las, TX
The BugSlug database is a relational database created using
Microsoft’s Access-97 program. Tables in the database include:
patient information, culture information (separate bacterial,
fungal, and viral tables), graft-versus-host disease data, and
drug susceptibility information. Data is obtained from the
BMT program clinical database and reports from Baylor Uni-
versity Medical Center’s Microbiology Department. Data is
analyzed on a quarterly basis. Types of data entered include:
diagnosis, preparative regimen, type and date of graft, date of
culture, type of culture, and pathogen, among others. If the
particular culture is tested for drug susceptibility, each drug
tested against the pathogen is statused as “Resistant”, “Inter-
mediate”, “Susceptible”, or “Not Tested”. Regular analyses of
data include: number of unique patient isolates per type of cul-
ture, unique positive bacterial and fungal isolates (per drug
susceptibility) per month, incidence of positive CMV antigene-
mia per month by disease and type of transplant, types of bac-
terial and fungal organisms isolated per source of culture, inci-
dence of common organisms per month, drug resistance
patterns for bacterial and fungal isolates, Vancomycin-resistant
Enterococcus resistance patterns per drug tested, common
bacterial and fungal organisms per graft, and unique positive
cultures at day post transplant. Correlation with incidence of
graft versus host disease and correlation with patient and
donor pre-transplant CMV status is also performed. Findings
are presented quarterly at BMT physicians’ meeting for review
and modification of standard prophylactic and prevention
practices. The minutes of the physicians’ meeting document
continuing quality assurance efforts of program as required by
FAHCT standards.
